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Figure 5. Depletion of
the gut microbiome was
associated with a
decrease on melanoma
Antibiotic
Antibiotic
tumor growth in the
Control
Control
brain. Tumor size at the
site of injection was
evaluated by histology (A)
and quantified using
ImageJ (B). Peripheral
immune profiling
demonstrate a decrease in
Tregs (C) and the CTLA4+
CD4 cells (D).

Figure 3. Tumor
microbiome overlaps
with oral microbiome,
suggesting the
possibility of direct
contribution. Alluvial
plots demonstrating the
overlap between
bacterial taxa in the
tumor microbiome and
gut (left) or oral (right)
microbiome.

CONCLUSIONS
• We identified distinct gut, oral, and tumor bacterial signatures that were
enriched in brain metastasis patients compared to primary tumors.
• Our findings suggest a direct contribution of the oral microbiome and the
potential indirect contribution of the gut microbiome to the development of
brain metastasis.
• Our pre-clinical findings demonstrate that the absence of gut microbiota
can regulate T cell activity to induce an anti-tumor response in the brain.
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Figure 2. Distinct microbial signatures in the gut, oral, and tumor
microbiome are enriched in brain metastasis compared to primary brain
tumors. Analysis of Compositions of Microbiomes with Bias Correction
(ANCOM-BC) demonstrating enrichment of taxa in samples from brain
metastasis patients (blue) and primary brain tumors (orange).
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Figure 4. Antibiotic
treatment was associated
Antibiotic
with alterations in the
Control
peripheral immune profile
in non-tumor bearing
mice. Gut microbiome
depletion increased the
circulating Treg population
(A) and the CTLA4+ CD4
and CD8 populations (B).
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BACKGROUND

We hypothesize that distinct gut and oral microbial signatures
contribute to the development of metastatic brain tumors.
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Figure 1. Schematics
demonstrating the
experimental design of
(A) clinical and (B)
animal studies.
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Background: Metastatic brain tumors are associated with significant morbidity
and mortality. The current limited understanding of the mechanisms underlying
brain metastasis has hindered the development of efficient diagnostics and
therapeutics for this disease. The microbiota has emerged as a novel hallmark
of cancer, with a prominent role in tumorigenesis, tumor immunity, and
response to treatment. However, the role of different microbial communities in
tumor metastasis, and in particular brain metastasis, is poorly understood. We
hypothesize that distinct microbial communities can alter the immune
microenvironment in the brain and affect brain metastasis development.
Methods: To evaluate the role of different microbial communities in brain
metastasis, matched stool, saliva, tumor, and plasma samples were collected
prospectively from patients with metastatic brain tumors who underwent
surgical tumor resection at the University of Texas MD Anderson Cancer
Center. Stool and saliva samples were collected using the OMNIgene
microbiome collection and stabilization kits (DNAgenotek, Kit # OM-200 and
OM-505, respectively). Tumor samples were flash frozen in sterile conditions.
Stool and saliva samples from 30 patients and tumor and plasma from 15
patients were sequenced via metagenomic shotgun and 16S rRNA
sequencing, respectively. Microbiome profiling was conducted through
established computational pipelines reported previously by our group. To
further explore the mechanistic role of the gut microbiota in brain metastasis,
we depleted gut microbiota in conventionally raised mice using a broadspectrum non-absorbable antibiotic regimen. Melanoma tumor cells were
subsequently injected intracranially to evaluate the effect of gut microbiota
depletion and associated immune changes on tumor growth. Tumor growth
was measured through in vivo bioluminescent imaging and histology.
Peripheral and tumor immune profiling was conducted through flow cytometry
and immunohistochemistry.
Results: In all types of microbiota evaluated in this study, distinct signatures
were identified to be associated with brain metastasis compared to other types
of brain tumors. Interestingly, we demonstrated an overlap between the tumor
microbiome and the oral microbiome but not with the gut microbiome. These
findings suggest a direct contribution of the oral microbiome and the potential
indirect contribution of the gut microbiome to the development of brain
metastasis. Our mechanistic studies on the role of gut microbiota in brain
metastasis demonstrated that depletion of the gut microbiota in mice
decreased tumor growth in the brain. Evaluation of the peripheral and tumor
immune profiles suggested the underlying mechanisms to involve alterations
in the circulating cytokine profiles and an increase in anti-tumor T cell activity.
Conclusion: Our clinical studies suggest the association of distinct microbial
communities with brain metastasis. Our pre-clinical findings demonstrate that
the absence of gut microbiota can modulate the regulation of T cell activity to
induce an anti-tumor response in the brain. Further studies, currently in
progress, will determine the individual and collective role of different microbial
communities in the development of brain metastasis.

• Gut and oral microbiome contributes to
different aspects of tumor progression1,2;
however, their role in primary and
metastatic brain tumors remains unknown.
• The gut-brain axis is the bidirectional
communication between the gut
microbiota and the brain and contributes
to a variety of neurological disorders 3.
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